| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pseudotumor Cerebri | 32 | 2021 | 43 | 9.610 |
Why?
|
| Papilledema | 17 | 2022 | 21 | 4.030 |
Why?
|
| Optic Nerve Glioma | 16 | 2022 | 16 | 3.880 |
Why?
|
| Intracranial Hypertension | 13 | 2022 | 53 | 3.850 |
Why?
|
| Vision Disorders | 21 | 2022 | 94 | 3.500 |
Why?
|
| Visual Acuity | 24 | 2022 | 236 | 3.000 |
Why?
|
| Optic Nerve | 11 | 2022 | 55 | 2.940 |
Why?
|
| Neurofibromatosis 1 | 13 | 2022 | 39 | 2.830 |
Why?
|
| Magnetic Resonance Imaging | 47 | 2020 | 2222 | 2.810 |
Why?
|
| Optic Neuritis | 11 | 2022 | 26 | 2.560 |
Why?
|
| Optic Nerve Diseases | 14 | 2022 | 31 | 2.110 |
Why?
|
| Headache | 11 | 2022 | 68 | 1.850 |
Why?
|
| Child | 61 | 2022 | 6401 | 1.850 |
Why?
|
| Optic Nerve Neoplasms | 8 | 2017 | 10 | 1.820 |
Why?
|
| Eye Movements | 4 | 2018 | 44 | 1.810 |
Why?
|
| Cerebrospinal Fluid Pressure | 7 | 2018 | 13 | 1.640 |
Why?
|
| Blindness | 3 | 2017 | 22 | 1.610 |
Why?
|
| Visual Cortex | 10 | 2007 | 67 | 1.570 |
Why?
|
| Neuroimaging | 8 | 2019 | 122 | 1.550 |
Why?
|
| Child, Preschool | 29 | 2022 | 3187 | 1.410 |
Why?
|
| Humans | 138 | 2022 | 68549 | 1.410 |
Why?
|
| Tomography, Optical Coherence | 12 | 2022 | 88 | 1.380 |
Why?
|
| Brain | 13 | 2019 | 2176 | 1.270 |
Why?
|
| Nystagmus, Pathologic | 2 | 2018 | 12 | 1.240 |
Why?
|
| Adolescent | 45 | 2022 | 8904 | 1.220 |
Why?
|
| Eye Diseases | 4 | 2017 | 38 | 1.210 |
Why?
|
| Male | 83 | 2022 | 37283 | 1.180 |
Why?
|
| Female | 88 | 2022 | 38021 | 1.180 |
Why?
|
| Visual Pathways | 9 | 2015 | 31 | 1.180 |
Why?
|
| Horner Syndrome | 4 | 2017 | 8 | 1.140 |
Why?
|
| Myasthenia Gravis | 3 | 2020 | 17 | 1.100 |
Why?
|
| Infant | 22 | 2022 | 2891 | 0.990 |
Why?
|
| Spinal Puncture | 7 | 2015 | 38 | 0.940 |
Why?
|
| Diplopia | 5 | 2019 | 14 | 0.930 |
Why?
|
| Neurology | 2 | 2017 | 43 | 0.930 |
Why?
|
| Amblyopia | 5 | 2022 | 43 | 0.910 |
Why?
|
| Brain Neoplasms | 5 | 2013 | 371 | 0.890 |
Why?
|
| Optic Atrophy, Hereditary, Leber | 1 | 2022 | 2 | 0.850 |
Why?
|
| Glioma | 3 | 2011 | 140 | 0.830 |
Why?
|
| Thymectomy | 2 | 2020 | 11 | 0.810 |
Why?
|
| Pupil | 2 | 2017 | 51 | 0.810 |
Why?
|
| Eye Diseases, Hereditary | 5 | 2021 | 10 | 0.810 |
Why?
|
| Societies, Medical | 2 | 2017 | 403 | 0.790 |
Why?
|
| Disease Management | 3 | 2017 | 248 | 0.770 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2020 | 6 | 0.760 |
Why?
|
| Diagnosis, Differential | 12 | 2021 | 1140 | 0.750 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2020 | 32 | 0.740 |
Why?
|
| Ophthalmoplegia | 5 | 2010 | 20 | 0.720 |
Why?
|
| Retrospective Studies | 29 | 2022 | 7268 | 0.710 |
Why?
|
| Follow-Up Studies | 15 | 2021 | 3256 | 0.690 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2019 | 2 | 0.690 |
Why?
|
| Orbital Diseases | 3 | 2017 | 21 | 0.680 |
Why?
|
| Biopsy | 5 | 2019 | 539 | 0.670 |
Why?
|
| Anisocoria | 2 | 2017 | 4 | 0.640 |
Why?
|
| Migraine with Aura | 1 | 2018 | 6 | 0.620 |
Why?
|
| Myofibroma | 1 | 2017 | 1 | 0.620 |
Why?
|
| Constriction | 1 | 2017 | 37 | 0.620 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2017 | 11 | 0.610 |
Why?
|
| Hemiplegia | 1 | 2018 | 29 | 0.610 |
Why?
|
| Vision, Monocular | 2 | 2020 | 7 | 0.610 |
Why?
|
| Terminology as Topic | 1 | 2018 | 141 | 0.600 |
Why?
|
| Ophthalmology | 1 | 2017 | 39 | 0.590 |
Why?
|
| Body Mass Index | 4 | 2016 | 866 | 0.590 |
Why?
|
| Hamartoma | 3 | 2013 | 24 | 0.580 |
Why?
|
| Oculomotor Muscles | 3 | 2017 | 54 | 0.570 |
Why?
|
| Intracranial Pressure | 8 | 2021 | 58 | 0.570 |
Why?
|
| Multiple Sclerosis | 3 | 2022 | 132 | 0.560 |
Why?
|
| Hypervitaminosis A | 1 | 2015 | 1 | 0.540 |
Why?
|
| Arachnoid Cysts | 2 | 2016 | 5 | 0.540 |
Why?
|
| Brain Diseases | 2 | 2018 | 78 | 0.530 |
Why?
|
| Optic Chiasm | 2 | 2006 | 3 | 0.530 |
Why?
|
| Adult | 31 | 2022 | 21379 | 0.520 |
Why?
|
| Prospective Studies | 18 | 2022 | 3703 | 0.510 |
Why?
|
| Surveys and Questionnaires | 5 | 2019 | 2798 | 0.500 |
Why?
|
| Vitamin A | 1 | 2015 | 111 | 0.500 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 158 | 0.500 |
Why?
|
| Headache Disorders | 1 | 2014 | 4 | 0.490 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 415 | 0.490 |
Why?
|
| Back Pain | 1 | 2014 | 30 | 0.490 |
Why?
|
| Alice in Wonderland Syndrome | 1 | 2014 | 1 | 0.480 |
Why?
|
| Tic Disorders | 1 | 2014 | 3 | 0.470 |
Why?
|
| Mydriasis | 1 | 2013 | 3 | 0.460 |
Why?
|
| Tonic Pupil | 2 | 2011 | 2 | 0.460 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2013 | 7 | 0.460 |
Why?
|
| Migraine Disorders | 1 | 2014 | 66 | 0.460 |
Why?
|
| Pain | 2 | 2016 | 472 | 0.450 |
Why?
|
| Dominance, Ocular | 2 | 2004 | 4 | 0.450 |
Why?
|
| Craniosynostoses | 3 | 2022 | 9 | 0.450 |
Why?
|
| Muscle, Smooth | 1 | 2013 | 117 | 0.440 |
Why?
|
| Geniculate Bodies | 4 | 2006 | 10 | 0.440 |
Why?
|
| Visual Perception | 3 | 2020 | 124 | 0.440 |
Why?
|
| Middle Aged | 24 | 2022 | 21119 | 0.440 |
Why?
|
| Urinary Bladder | 1 | 2013 | 108 | 0.430 |
Why?
|
| Vision Tests | 3 | 2022 | 18 | 0.430 |
Why?
|
| Neuroblastoma | 2 | 2011 | 109 | 0.430 |
Why?
|
| Colon | 1 | 2013 | 168 | 0.430 |
Why?
|
| Ultrasonography | 6 | 2021 | 453 | 0.420 |
Why?
|
| Psychophysiologic Disorders | 1 | 2012 | 20 | 0.420 |
Why?
|
| Sphenoid Sinusitis | 1 | 2012 | 4 | 0.420 |
Why?
|
| Aspergillosis | 1 | 2012 | 20 | 0.420 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2012 | 8 | 0.420 |
Why?
|
| POEMS Syndrome | 1 | 2012 | 2 | 0.420 |
Why?
|
| Meningitis | 1 | 2012 | 23 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2012 | 467 | 0.410 |
Why?
|
| Skull Base Neoplasms | 1 | 2012 | 13 | 0.410 |
Why?
|
| Plasmacytoma | 1 | 2012 | 15 | 0.410 |
Why?
|
| Mycophenolic Acid | 1 | 2012 | 62 | 0.410 |
Why?
|
| Ocular Motility Disorders | 1 | 2011 | 15 | 0.410 |
Why?
|
| Myopia | 1 | 2012 | 27 | 0.400 |
Why?
|
| Immunoglobulin G | 3 | 2021 | 481 | 0.400 |
Why?
|
| Oculomotor Nerve Diseases | 5 | 2016 | 6 | 0.400 |
Why?
|
| Central Nervous System | 1 | 2012 | 107 | 0.390 |
Why?
|
| Blepharoptosis | 2 | 2010 | 7 | 0.390 |
Why?
|
| Cross-Sectional Studies | 9 | 2021 | 2265 | 0.390 |
Why?
|
| Prognosis | 8 | 2019 | 2093 | 0.380 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2010 | 17 | 0.370 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2011 | 99 | 0.370 |
Why?
|
| Optic Disk | 3 | 2021 | 37 | 0.360 |
Why?
|
| Risk Assessment | 1 | 2016 | 2004 | 0.360 |
Why?
|
| Vision, Binocular | 3 | 2020 | 30 | 0.360 |
Why?
|
| Anniversaries and Special Events | 1 | 2010 | 12 | 0.360 |
Why?
|
| Patient Positioning | 1 | 2010 | 15 | 0.360 |
Why?
|
| Autistic Disorder | 1 | 2010 | 77 | 0.340 |
Why?
|
| Liver Transplantation | 1 | 2012 | 400 | 0.330 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 142 | 0.320 |
Why?
|
| Young Adult | 12 | 2022 | 5710 | 0.310 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 3 | 2022 | 17 | 0.300 |
Why?
|
| Sex Distribution | 3 | 2016 | 272 | 0.300 |
Why?
|
| Age Factors | 5 | 2016 | 1860 | 0.280 |
Why?
|
| Nerve Fibers | 5 | 2021 | 77 | 0.270 |
Why?
|
| Visual Fields | 6 | 2020 | 41 | 0.270 |
Why?
|
| Obesity | 4 | 2016 | 1074 | 0.270 |
Why?
|
| Risk Factors | 10 | 2022 | 5720 | 0.270 |
Why?
|
| Sensitivity and Specificity | 7 | 2019 | 1753 | 0.260 |
Why?
|
| Immunosuppressive Agents | 3 | 2017 | 514 | 0.260 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2005 | 31 | 0.250 |
Why?
|
| Cohort Studies | 5 | 2022 | 2356 | 0.240 |
Why?
|
| Alexia, Pure | 1 | 2004 | 1 | 0.240 |
Why?
|
| Stroke | 2 | 2016 | 2162 | 0.240 |
Why?
|
| Glucocorticoids | 4 | 2016 | 222 | 0.230 |
Why?
|
| Retinal Ganglion Cells | 4 | 2021 | 72 | 0.230 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1054 | 0.230 |
Why?
|
| Thalamus | 1 | 2004 | 82 | 0.230 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 191 | 0.230 |
Why?
|
| Temporal Arteries | 2 | 2019 | 7 | 0.220 |
Why?
|
| Giant Cell Arteritis | 2 | 2019 | 10 | 0.220 |
Why?
|
| United States | 5 | 2020 | 7338 | 0.220 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2022 | 3 | 0.220 |
Why?
|
| Treatment Outcome | 4 | 2020 | 7028 | 0.220 |
Why?
|
| Morbidity | 2 | 2016 | 130 | 0.210 |
Why?
|
| Neuromyelitis Optica | 1 | 2022 | 1 | 0.210 |
Why?
|
| DNA, Mitochondrial | 1 | 2022 | 84 | 0.200 |
Why?
|
| Age Distribution | 2 | 2016 | 319 | 0.200 |
Why?
|
| Steroids | 1 | 2022 | 84 | 0.200 |
Why?
|
| Geographic Mapping | 1 | 2021 | 19 | 0.190 |
Why?
|
| Diabetic Retinopathy | 1 | 2022 | 110 | 0.190 |
Why?
|
| Exophthalmos | 2 | 2017 | 6 | 0.190 |
Why?
|
| Diuretics | 2 | 2014 | 96 | 0.190 |
Why?
|
| Immunologic Factors | 1 | 2021 | 87 | 0.190 |
Why?
|
| Autoantibodies | 2 | 2021 | 434 | 0.190 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 34 | 0.180 |
Why?
|
| Receptors, Cholinergic | 1 | 2020 | 30 | 0.180 |
Why?
|
| History, 20th Century | 2 | 2011 | 248 | 0.180 |
Why?
|
| Aged | 11 | 2020 | 14842 | 0.180 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 96 | 0.180 |
Why?
|
| Reference Values | 4 | 2020 | 579 | 0.170 |
Why?
|
| Orbit | 2 | 2012 | 30 | 0.170 |
Why?
|
| Time Factors | 2 | 2018 | 4655 | 0.170 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 951 | 0.170 |
Why?
|
| Cavernous Sinus | 2 | 2012 | 10 | 0.160 |
Why?
|
| Acetazolamide | 2 | 2016 | 8 | 0.160 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2018 | 16 | 0.160 |
Why?
|
| Prevalence | 2 | 2014 | 1609 | 0.160 |
Why?
|
| Chlorobenzenes | 1 | 2018 | 8 | 0.160 |
Why?
|
| Eye Pain | 1 | 2017 | 3 | 0.150 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 955 | 0.150 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 240 | 0.150 |
Why?
|
| Orbital Myositis | 1 | 2017 | 1 | 0.150 |
Why?
|
| Eye Neoplasms | 1 | 2017 | 10 | 0.150 |
Why?
|
| Susac Syndrome | 1 | 2017 | 1 | 0.150 |
Why?
|
| Muscle Neoplasms | 1 | 2017 | 9 | 0.150 |
Why?
|
| Retinal Artery Occlusion | 1 | 2017 | 7 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.150 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 115 | 0.140 |
Why?
|
| Neurosurgical Procedures | 1 | 2018 | 98 | 0.140 |
Why?
|
| Occipital Lobe | 1 | 2016 | 18 | 0.140 |
Why?
|
| Sexual Maturation | 1 | 2016 | 10 | 0.140 |
Why?
|
| Radiosurgery | 1 | 2017 | 66 | 0.140 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2016 | 19 | 0.140 |
Why?
|
| Radiation Injuries | 1 | 2017 | 97 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 369 | 0.140 |
Why?
|
| Carotid Artery, Internal | 2 | 2015 | 85 | 0.140 |
Why?
|
| DNA | 1 | 2019 | 597 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 503 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 627 | 0.130 |
Why?
|
| Hemianopsia | 2 | 2006 | 8 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 201 | 0.130 |
Why?
|
| Trochlear Nerve Diseases | 2 | 2013 | 2 | 0.130 |
Why?
|
| Abducens Nerve Diseases | 2 | 2013 | 5 | 0.130 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2015 | 5 | 0.130 |
Why?
|
| Acute Disease | 3 | 2013 | 658 | 0.130 |
Why?
|
| Myelin Sheath | 1 | 2015 | 115 | 0.130 |
Why?
|
| Vitamins | 1 | 2015 | 134 | 0.120 |
Why?
|
| Cerebrospinal Fluid | 1 | 2014 | 23 | 0.120 |
Why?
|
| Demyelinating Diseases | 1 | 2015 | 57 | 0.120 |
Why?
|
| Hospitalization | 1 | 2020 | 977 | 0.120 |
Why?
|
| Furosemide | 1 | 2014 | 45 | 0.120 |
Why?
|
| Incidence | 3 | 2017 | 1582 | 0.120 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2014 | 52 | 0.120 |
Why?
|
| Tinnitus | 1 | 2014 | 22 | 0.120 |
Why?
|
| Fructose | 1 | 2014 | 51 | 0.120 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2014 | 150 | 0.120 |
Why?
|
| Pituitary-Adrenal System | 1 | 2014 | 138 | 0.120 |
Why?
|
| Vincristine | 2 | 2012 | 44 | 0.120 |
Why?
|
| Aging | 1 | 2020 | 911 | 0.120 |
Why?
|
| Electroencephalography | 2 | 2014 | 418 | 0.120 |
Why?
|
| Retinal Hemorrhage | 1 | 2013 | 7 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2077 | 0.110 |
Why?
|
| Antimitotic Agents | 1 | 2013 | 1 | 0.110 |
Why?
|
| Weight Reduction Programs | 1 | 2014 | 67 | 0.110 |
Why?
|
| Remission, Spontaneous | 1 | 2013 | 25 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 2324 | 0.110 |
Why?
|
| Interviews as Topic | 1 | 2014 | 392 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2014 | 222 | 0.110 |
Why?
|
| Abnormalities, Multiple | 1 | 2013 | 109 | 0.110 |
Why?
|
| Sex Factors | 1 | 2016 | 1265 | 0.110 |
Why?
|
| Eye Infections, Fungal | 1 | 2012 | 7 | 0.110 |
Why?
|
| Aspergillus fumigatus | 1 | 2012 | 27 | 0.110 |
Why?
|
| Vinblastine | 1 | 2012 | 40 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 110 | 0.100 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 182 | 0.100 |
Why?
|
| Biomarkers | 2 | 2022 | 1593 | 0.100 |
Why?
|
| Asthma | 1 | 2016 | 345 | 0.100 |
Why?
|
| Carboplatin | 1 | 2012 | 59 | 0.100 |
Why?
|
| Logistic Models | 2 | 2016 | 1419 | 0.100 |
Why?
|
| Reflex, Pupillary | 1 | 2011 | 5 | 0.100 |
Why?
|
| Eyelids | 1 | 2011 | 11 | 0.100 |
Why?
|
| London | 1 | 2011 | 12 | 0.100 |
Why?
|
| Fixation, Ocular | 1 | 2011 | 13 | 0.100 |
Why?
|
| Accommodation, Ocular | 1 | 2011 | 9 | 0.100 |
Why?
|
| Saccades | 1 | 2011 | 17 | 0.100 |
Why?
|
| Erdheim-Chester Disease | 1 | 2011 | 2 | 0.100 |
Why?
|
| Contrast Sensitivity | 1 | 2011 | 28 | 0.100 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2011 | 12 | 0.100 |
Why?
|
| Minnesota | 1 | 2011 | 27 | 0.100 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2011 | 4 | 0.100 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 317 | 0.100 |
Why?
|
| Neurologic Examination | 1 | 2011 | 107 | 0.100 |
Why?
|
| Visual Field Tests | 3 | 2009 | 8 | 0.100 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2013 | 211 | 0.100 |
Why?
|
| Australia | 1 | 2011 | 235 | 0.090 |
Why?
|
| Light | 1 | 2011 | 152 | 0.090 |
Why?
|
| Optic Atrophy | 1 | 2010 | 2 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1549 | 0.090 |
Why?
|
| Pyridostigmine Bromide | 1 | 2010 | 11 | 0.090 |
Why?
|
| Ectropion | 1 | 2010 | 3 | 0.090 |
Why?
|
| Iris Neoplasms | 1 | 2010 | 5 | 0.090 |
Why?
|
| Astrocytoma | 1 | 2010 | 30 | 0.090 |
Why?
|
| Philadelphia | 1 | 2010 | 18 | 0.090 |
Why?
|
| Graves Ophthalmopathy | 2 | 2006 | 4 | 0.090 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2009 | 15 | 0.090 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2009 | 17 | 0.090 |
Why?
|
| Mitochondria | 1 | 2014 | 643 | 0.090 |
Why?
|
| Vitreous Body | 1 | 2009 | 26 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 848 | 0.090 |
Why?
|
| Comorbidity | 1 | 2014 | 1425 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2010 | 126 | 0.090 |
Why?
|
| Neural Pathways | 1 | 2011 | 323 | 0.090 |
Why?
|
| Survival Rate | 1 | 2012 | 1055 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 799 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2013 | 4843 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2012 | 301 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 648 | 0.080 |
Why?
|
| Disease Progression | 2 | 2012 | 1037 | 0.080 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2007 | 16 | 0.080 |
Why?
|
| Lateral Sinus Thrombosis | 1 | 2007 | 1 | 0.080 |
Why?
|
| Mastoiditis | 1 | 2007 | 3 | 0.080 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 189 | 0.080 |
Why?
|
| Photic Stimulation | 2 | 2006 | 229 | 0.080 |
Why?
|
| Retina | 2 | 2021 | 252 | 0.070 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2007 | 6 | 0.070 |
Why?
|
| Diphtheria Toxin | 1 | 2007 | 18 | 0.070 |
Why?
|
| Lymphoma, T-Cell | 1 | 2007 | 19 | 0.070 |
Why?
|
| Vanilmandelic Acid | 1 | 2006 | 6 | 0.070 |
Why?
|
| Motion Perception | 1 | 2006 | 8 | 0.070 |
Why?
|
| Homovanillic Acid | 1 | 2006 | 52 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2006 | 27 | 0.070 |
Why?
|
| Interleukin-2 | 1 | 2007 | 133 | 0.070 |
Why?
|
| Echo-Planar Imaging | 1 | 2006 | 17 | 0.070 |
Why?
|
| Weight Gain | 1 | 2007 | 135 | 0.070 |
Why?
|
| Arteriovenous Malformations | 1 | 2006 | 34 | 0.070 |
Why?
|
| Strabismus | 1 | 2006 | 37 | 0.070 |
Why?
|
| Afferent Pathways | 1 | 2005 | 31 | 0.070 |
Why?
|
| Form Perception | 1 | 2005 | 16 | 0.070 |
Why?
|
| Orientation | 1 | 2005 | 31 | 0.070 |
Why?
|
| Psychomotor Performance | 1 | 2007 | 213 | 0.070 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2005 | 10 | 0.070 |
Why?
|
| Orbital Neoplasms | 1 | 2005 | 21 | 0.070 |
Why?
|
| Rhabdomyosarcoma | 1 | 2005 | 36 | 0.060 |
Why?
|
| Pattern Recognition, Visual | 1 | 2005 | 69 | 0.060 |
Why?
|
| Oxyhemoglobins | 1 | 2005 | 3 | 0.060 |
Why?
|
| Consensus | 2 | 2018 | 211 | 0.060 |
Why?
|
| Sensory Thresholds | 1 | 2004 | 50 | 0.060 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2004 | 4 | 0.060 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2004 | 15 | 0.060 |
Why?
|
| Apraxias | 1 | 2004 | 4 | 0.060 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2004 | 6 | 0.060 |
Why?
|
| Ataxia | 1 | 2004 | 11 | 0.060 |
Why?
|
| Agnosia | 1 | 2004 | 9 | 0.060 |
Why?
|
| Arteriovenous Fistula | 1 | 2004 | 25 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2005 | 120 | 0.060 |
Why?
|
| Syndrome | 3 | 2014 | 255 | 0.060 |
Why?
|
| Cranial Nerve Diseases | 1 | 2004 | 14 | 0.060 |
Why?
|
| Motor Neuron Disease | 1 | 2004 | 10 | 0.060 |
Why?
|
| Burkitt Lymphoma | 1 | 2004 | 18 | 0.060 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2004 | 30 | 0.060 |
Why?
|
| Pituitary Apoplexy | 1 | 2003 | 4 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2004 | 164 | 0.060 |
Why?
|
| Lasers | 1 | 2003 | 61 | 0.060 |
Why?
|
| Anisometropia | 1 | 2003 | 12 | 0.060 |
Why?
|
| Blood Sedimentation | 2 | 2019 | 16 | 0.060 |
Why?
|
| Vision Screening | 1 | 2003 | 40 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2003 | 75 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2009 | 1070 | 0.060 |
Why?
|
| Hospitals, Pediatric | 2 | 2014 | 114 | 0.060 |
Why?
|
| Scotoma | 1 | 2022 | 4 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 375 | 0.050 |
Why?
|
| Riboflavin | 1 | 2022 | 15 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 25 | 0.050 |
Why?
|
| Skull | 1 | 2021 | 63 | 0.050 |
Why?
|
| Decompression, Surgical | 1 | 2021 | 55 | 0.050 |
Why?
|
| Pennsylvania | 1 | 2021 | 46 | 0.050 |
Why?
|
| Neuroglia | 1 | 2002 | 136 | 0.050 |
Why?
|
| Acid Sensing Ion Channels | 1 | 2020 | 3 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 1172 | 0.050 |
Why?
|
| ROC Curve | 1 | 2021 | 392 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 266 | 0.040 |
Why?
|
| Poverty | 1 | 2021 | 218 | 0.040 |
Why?
|
| Transverse Sinuses | 1 | 2019 | 3 | 0.040 |
Why?
|
| Sclera | 1 | 2019 | 8 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 2019 | 29 | 0.040 |
Why?
|
| Cranial Sinuses | 1 | 2019 | 11 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 444 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2004 | 565 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 242 | 0.040 |
Why?
|
| Quality of Life | 1 | 2007 | 1515 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1851 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 236 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 180 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2019 | 159 | 0.040 |
Why?
|
| Fundus Oculi | 1 | 2017 | 33 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2017 | 84 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2017 | 89 | 0.040 |
Why?
|
| Fluorescein Angiography | 1 | 2017 | 57 | 0.040 |
Why?
|
| Pituitary Neoplasms | 1 | 2017 | 52 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2016 | 32 | 0.040 |
Why?
|
| Hydrocephalus | 1 | 2017 | 40 | 0.040 |
Why?
|
| Craniotomy | 1 | 2016 | 33 | 0.040 |
Why?
|
| Animals | 1 | 2014 | 20880 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 785 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 349 | 0.040 |
Why?
|
| Growth | 1 | 2016 | 17 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 330 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 652 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2016 | 35 | 0.030 |
Why?
|
| Neurons | 1 | 2002 | 881 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 946 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2016 | 187 | 0.030 |
Why?
|
| Ketoglutaric Acids | 1 | 2014 | 4 | 0.030 |
Why?
|
| Succinic Acid | 1 | 2014 | 9 | 0.030 |
Why?
|
| Body Constitution | 1 | 2014 | 24 | 0.030 |
Why?
|
| Hydrodynamics | 1 | 2014 | 15 | 0.030 |
Why?
|
| Aldosterone | 1 | 2014 | 51 | 0.030 |
Why?
|
| Adipokines | 1 | 2014 | 20 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2017 | 419 | 0.030 |
Why?
|
| Intraocular Pressure | 1 | 2015 | 143 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2016 | 298 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1341 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2015 | 181 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2014 | 291 | 0.030 |
Why?
|
| Anisotropy | 1 | 2013 | 105 | 0.030 |
Why?
|
| Overweight | 1 | 2014 | 186 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 737 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 86 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 424 | 0.030 |
Why?
|
| Hypopituitarism | 1 | 2011 | 5 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2013 | 249 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2014 | 332 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2003 | 234 | 0.020 |
Why?
|
| Models, Biological | 1 | 2014 | 981 | 0.020 |
Why?
|
| Hydrolases | 1 | 2009 | 20 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 521 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 114 | 0.020 |
Why?
|
| Cytokines | 1 | 2012 | 866 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2009 | 290 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 696 | 0.020 |
Why?
|
| Remission Induction | 1 | 2007 | 111 | 0.020 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 2006 | 4 | 0.020 |
Why?
|
| Abdominal Neoplasms | 1 | 2006 | 22 | 0.020 |
Why?
|
| Eyelid Diseases | 1 | 2006 | 7 | 0.020 |
Why?
|
| Sarcoma, Ewing | 1 | 2006 | 26 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2009 | 342 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 100 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 381 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 376 | 0.020 |
Why?
|
| Pupil Disorders | 1 | 2004 | 3 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 2004 | 50 | 0.020 |
Why?
|
| Health Status | 1 | 2007 | 429 | 0.010 |
Why?
|
| Leucovorin | 1 | 2004 | 35 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2007 | 438 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 2004 | 151 | 0.010 |
Why?
|
| Oxygen | 1 | 2006 | 386 | 0.010 |
Why?
|
| Psychometrics | 1 | 2006 | 514 | 0.010 |
Why?
|
| Hypertension | 1 | 2013 | 1533 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 129 | 0.010 |
Why?
|
| Methotrexate | 1 | 2004 | 91 | 0.010 |
Why?
|
| Jaw Diseases | 1 | 2003 | 7 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2003 | 249 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 2003 | 99 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 334 | 0.010 |
Why?
|
| Fever | 1 | 2003 | 96 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 772 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 1329 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 561 | 0.010 |
Why?
|